BR112014026740A8 - anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo - Google Patents

anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo

Info

Publication number
BR112014026740A8
BR112014026740A8 BR112014026740A BR112014026740A BR112014026740A8 BR 112014026740 A8 BR112014026740 A8 BR 112014026740A8 BR 112014026740 A BR112014026740 A BR 112014026740A BR 112014026740 A BR112014026740 A BR 112014026740A BR 112014026740 A8 BR112014026740 A8 BR 112014026740A8
Authority
BR
Brazil
Prior art keywords
antibody
composition
providing
enhanced adcc
antibodies
Prior art date
Application number
BR112014026740A
Other languages
English (en)
Other versions
BR112014026740B1 (pt
BR112014026740A2 (pt
Inventor
Frey Gerhar
Wen Chang Hwai
M Short Jay
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of BR112014026740A2 publication Critical patent/BR112014026740A2/pt
Publication of BR112014026740A8 publication Critical patent/BR112014026740A8/pt
Publication of BR112014026740B1 publication Critical patent/BR112014026740B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo. a presente invenção refere-se a regiões de fc modificadas de anticorpos, e usos das mesmas, tais como em anticorpos que contêm uma região de fc da presente invenção.
BR112014026740-5A 2012-04-27 2013-04-26 Anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo BR112014026740B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
US61/639/729 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Publications (3)

Publication Number Publication Date
BR112014026740A2 BR112014026740A2 (pt) 2017-06-27
BR112014026740A8 true BR112014026740A8 (pt) 2021-06-15
BR112014026740B1 BR112014026740B1 (pt) 2022-10-04

Family

ID=49483948

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026740-5A BR112014026740B1 (pt) 2012-04-27 2013-04-26 Anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo

Country Status (13)

Country Link
US (2) US20150065690A1 (pt)
EP (2) EP2841458A4 (pt)
JP (1) JP6470170B2 (pt)
KR (2) KR20200037434A (pt)
CN (1) CN104428317B (pt)
AU (3) AU2013251309B2 (pt)
BR (1) BR112014026740B1 (pt)
CA (1) CA2871807C (pt)
HK (1) HK1207654A1 (pt)
IN (1) IN2014DN08721A (pt)
MX (1) MX360368B (pt)
RU (1) RU2014147741A (pt)
WO (1) WO2013163630A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143138T3 (da) 2014-05-13 2022-04-25 Bioatla Inc Betinget aktive biologiske proteiner
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
JP7155008B2 (ja) * 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
SG11202104373YA (en) * 2018-10-31 2021-05-28 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20230026259A1 (en) 2019-03-08 2023-01-26 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP4014050A1 (en) 2019-08-12 2022-06-22 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021234655A2 (en) * 2020-05-21 2021-11-25 Cadila Healthcare Limited Fc variant and preparation thereof
CN115803091A (zh) 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
KR20230093483A (ko) 2020-10-29 2023-06-27 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
JP2024509543A (ja) 2021-03-03 2024-03-04 フォーマイコン アーゲー ＡＣＥ２ Ｆｃ融合タンパク質の製剤
WO2023094507A1 (en) 2021-11-24 2023-06-01 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4768439B2 (ja) * 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003280247A1 (en) 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
SI2573114T1 (sl) * 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
US7790655B2 (en) * 2005-10-14 2010-09-07 Medimmune, Llc Cell display of antibody libraries
EP4098661A1 (en) * 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CN103298834A (zh) * 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
EP2731781B1 (en) 2011-07-15 2016-05-18 Basell Poliolefine Italia S.r.l. Polyolefin strap comprising a random copolymer of propylene with 1-hexene
BR112014007353B1 (pt) * 2011-09-30 2022-09-13 Chugai Seiyaku Kabushiki Kaisha Biblioteca de anticorpos dependentes de concentração de íon
AU2012366290A1 (en) * 2012-01-19 2014-08-07 Therapeutic Proteins International, LLC Stabilization of the anti-CD20 antibody Rituximab

Also Published As

Publication number Publication date
EP2841458A4 (en) 2015-09-16
KR20200037434A (ko) 2020-04-08
US20180186863A1 (en) 2018-07-05
AU2013251309B2 (en) 2017-06-22
MX360368B (es) 2018-10-29
JP6470170B2 (ja) 2019-02-13
KR20150008082A (ko) 2015-01-21
RU2014147741A (ru) 2016-06-20
EP3470433A1 (en) 2019-04-17
IN2014DN08721A (pt) 2015-05-22
AU2019202229A1 (en) 2019-04-18
AU2017225111A1 (en) 2017-09-28
BR112014026740B1 (pt) 2022-10-04
CA2871807A1 (en) 2013-10-31
BR112014026740A2 (pt) 2017-06-27
JP2015515497A (ja) 2015-05-28
CN104428317A (zh) 2015-03-18
HK1207654A1 (en) 2016-02-05
EP2841458A1 (en) 2015-03-04
AU2013251309A1 (en) 2014-10-30
MX2014012978A (es) 2015-02-05
WO2013163630A1 (en) 2013-10-31
AU2019202229B2 (en) 2021-02-11
AU2017225111B2 (en) 2019-01-03
CN104428317B (zh) 2018-08-28
US10954288B2 (en) 2021-03-23
CA2871807C (en) 2022-10-04
US20150065690A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
AR095232A1 (es) Métodos y composiciones para el control de malezas
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
BR112016015105A2 (pt) Conjugados var2csa-droga
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BR112012028764A2 (pt) anticor-pos antifgfr2
BR112012018021A2 (pt) antídotos anticoagulantes.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/04/2013, OBSERVADAS AS CONDICOES LEGAIS